These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7539582)

  • 1. Etoposide, dexamethasone, and continuous-infusion cyclophosphamide with G-CSF for VAD-resistant multiple myeloma.
    Grau E; Real E; Torrecillas MT
    Am J Hematol; 1995 Jun; 49(2):170. PubMed ID: 7539582
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol.
    Giles FJ; Wickham NR; Rapoport BL; Somlo G; Lim SW; Shan J; Lynott AM
    Am J Hematol; 2000 Mar; 63(3):125-30. PubMed ID: 10679801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma.
    Dimopoulos MA; Delasalle KB; Champlin R; Alexanian R
    Br J Haematol; 1993 Feb; 83(2):240-4. PubMed ID: 8457473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of DCEP mobilizing regimen in in vivo purging of PBSC harvests in multiple myeloma.
    Novella E; Madeo D; Albiero E; Roberti S; Castaman G; Elice F; Rodeghiero F
    Leuk Lymphoma; 2004 Jul; 45(7):1497-9. PubMed ID: 15359659
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
    Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive sequential therapy for VAD-resistant multiple myeloma.
    Dimopoulos MA; Weber DM; Hester J; Delasalle K; Champlin R; Alexanian R
    Leuk Lymphoma; 1994 May; 13(5-6):479-84. PubMed ID: 7915163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
    Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Hagiwara S; Miwa A
    Int J Hematol; 2018 May; 107(5):559-567. PubMed ID: 29388164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
    Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents.
    Ronchetti AM; Isnard F; Buffet M; Coman T; Gorin NC; Coppo P; Garderet L; Malak S
    Leuk Lymphoma; 2013 May; 54(5):1117-9. PubMed ID: 23035656
    [No Abstract]   [Full Text] [Related]  

  • 11. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
    Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
    J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].
    Adam Z; Elbl L; Vorlícek J; Hájek R; Tomíska M; Hejlová N; Králová E; Novotná H
    Vnitr Lek; 1994 Aug; 40(8):506-12. PubMed ID: 7941437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of multiple myeloma resistant to alkylating agents with dexamethasone, vincristine and adriamycin in continuous infusion].
    Monconduit M; Le Loët X; Bernard JF; Menard JF; Grosbois B; Michaux JL; De Gramont A; Laporte JP; Najman A; Jouet JP
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):477-9. PubMed ID: 3616472
    [No Abstract]   [Full Text] [Related]  

  • 14. Resistant multiple myeloma treated with mitozantrone in combination with vincristine and dexamethasone (MOD).
    Phillips JK
    Eur J Haematol; 1989 Jan; 42(1):109-10. PubMed ID: 2914592
    [No Abstract]   [Full Text] [Related]  

  • 15. Etoposide and ifosfamide for MP (melphalan and prednisolone)- and VAD (vincristine, adriamycin and dexamethasone)-resistant plasma cell myeloma: a case report.
    Ikeda K; Abe N; Morioka A; Inoo M; Nagai M; Kubota Y; Irino S
    Jpn J Med; 1990; 29(5):516-8. PubMed ID: 2089176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
    Barlogie B; Velasquez WS; Alexanian R; Cabanillas F
    J Clin Oncol; 1989 Oct; 7(10):1514-7. PubMed ID: 2778481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
    Bilgrami S; Bona RD; Edwards RL; Li Z; Naqvi B; Shaikh A; Furlong F; Fox J; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2001 Jul; 28(2):137-43. PubMed ID: 11509931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
    Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
    Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.